Bitcoin eyes all-time high with 4% gap as ETFs attract massive inflows
Bitcoin nears historic peak as ETFs experience unprecedented inflows, signaling robust investor confidence. The post Bitcoin eyes all-time high with 4% gap as ETFs attract massive inflows appeared first on Crypto Briefin...
Archive context
Older archive item. Useful for background and entity history, but not a fresh market-moving signal.
Bitcoin nears historic peak as ETFs experience unprecedented inflows, signaling robust investor confidence.
The post Bitcoin eyes all-time high with 4% gap as ETFs attract massive inflows appeared first on Crypto Briefing.
Why this matters
This bitcoin story adds another data point to the current market tape and is useful when read alongside nearby source coverage.
Original source
Read on Crypto BriefingRelated market context
Hyperliquid Stays Near All-Time High, Even as Bitcoin ETFs Lose $6.5 Billion
Even as billions of dollars exit major crypto investment products, Hyperliquid’s HYPE token has remained resilient despite heavy w...
Bitcoin and Solana ETFs see renewed inflows after heavy selling
Renewed inflows into Bitcoin and Solana ETFs suggest potential market stabilization and increased investor confidence in crypto as...
Bitcoin sees highest transaction activity in 17 years, market eyes $67,500 in July
Increased Bitcoin transaction activity signals growing network utility, potentially boosting market confidence and influencing pri...
Egypt nears first World Cup quarterfinal led by Mo Salah, and crypto traders are paying attention
Egypt's World Cup success could redefine sports-driven crypto market dynamics, highlighting the volatile interplay between sports...
Wintermute cautions Bitcoin relief rally likely as price hits multi-week high
Bitcoin's recent price rise may be temporary, as sustained growth requires stronger crypto-specific demand and institutional engag...
Nasdaq arthritis company holding Moshe Hogeg crypto hits all-time low
As of 8:19am today in New York, every retail investor who had ever bought shares of Enlivex on the Nasdaq, an arthritis biotech-tu...